Connexin 26 gene therapy of human bladder cancer: Induction of growth suppression, apoptosis, and synergy with cisplatin

Human Gene Therapy

Volumn 12, Issue 18, 2001, Pages 2225-2236

  Tanaka, Motoyoshi ^a   Grossman, H Barton ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CONNEXIN 26; RECOMBINANT DNA; VIRUS VECTOR;

ADENOVIRUS; APOPTOSIS; ARTICLE; BLADDER; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CISPLATIN; COMBINED MODALITY THERAPY; CONNEXINS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 0035693396     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340152710568     Document Type: Article

References (54)

1. Thymidine kinase-mediated killing of rat brain tumors
2. Gap junctions: New tools, new answers, new questions
3. Vectors in cancer therapy: How will they deliver?
4. Connections with connexins: The molecular basis of direct intercellular signaling
5. Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy
6. In vitro and in vivo effects of retrovirus-mediated transfer of the connexin 43 gene in malignant gliomas: Consequences for HSVtk/GCV anticancer gene therapy
7. The treated natural history of high risk superficial bladder cancer: 15-Year outcome
8. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
9. Gap junctions in the brain: Where, what type, how many and why?
10. cis-Diamminedichloroplatinum(II): Effects of a representative metal coordination complex on mammalian cells
11. Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase/ganciclovir gene therapy
12. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
13. Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy
14. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
15. Actions of HSVtk and connexin43 gene delivery on gap junctional communication and drug sensitization in hepatocellular carcinoma
16. Methods for construction of adenovirus vectors
17. Superficial bladder cancer: Decreasing the risk of recurrence
18. Improved growth of human urothelial carcinoma cell cultures
19. Decreased connexin expression and intercellular communication in human bladder cancer cells
20. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein
21. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients
22. Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary cells and restore differentiation potential
23. Cdc2-mediated phosphorylation of the gap junction protein, connexin 43, during mitosis
24. Connexin 26 mutations in hereditary non-syndromic sensorineural deafness
25. Connexin expression and intercellular communication in two- and three-dimensional in vitro cultures of human bladder carcinoma
26. 1 with laminin 5 promotes gap junctional communication
27. Transcriptional down-regulation of gap junction proteins blocks junctional communication in mammary cell lines
28. The monoclonal antibody BQ16 identifies the a6b4 integrin on bladder cancer
29. Properties of connexin26 gap junctional proteins derived from mutations associated with non-syndromal hereditary deafness
30. Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin 43 gap junction formation
31. Negative growth control of HeLa cells by connexin gene: Connexin species specificity
32. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexin
33. A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells
34. Assignment of connexin 26 (GJB2) and 46 (GJA3) genes to human chromosome 13q11 → q12 and mouse chromosome 14D1-E1 by in situ hybridization
35. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer
36. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
37. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene
38. Gap junction proteins connexin32 and connexin43 partially acquire growth-suppressive function in HeLa cells by deletion of their C-terminal tails
39. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
40. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
41. Two molecular pathways to transitional cell carcinoma of the bladder
42. Tyrosine phosphorylation of the gap junction protein connexin 43 is required for the pp60v-src-induced inhibition of communication
43. Connexin 26 is methylated in a high proportion of breast cancer patients
44. Gelsolin: A candidate for suppressor of human bladder cancer
45. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells
46. Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery
47. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: Clinical and biologic aspects
48. The bystander effect by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions
49. Characterization of the mitogen-activated protein kinase phosphorylation sites on the connexin-43 gap junction protein
50. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer
51. Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues
52. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells
53. Hypermethylation of connexin 32 gene as a mechanism of disruption of cell-cell communication in tumors